返回
M
Maged W. Helmy
Damanhour University
37H指数
157论文数
3.5K被引数
收录论文 64
发表时间
Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models通过抑制PD-1/PD-L1和CTLA-4抑制性免疫检查点以及相关的致癌通路,将baricitinib和/或rosuvastatin重新用于激活肺癌模型中的抗肿瘤免疫反应。
Corrigendum to “Combination of magnetic targeting with synergistic inhibition of NF-κB and glutathione via micellar drug nanomedicine enhances its anti-tumor efficacy.” [Eur. J. Pharm. Biopharm. 155 (2020) 162–176]勘误:“通过胶束药物纳米药物将磁靶向与协同抑制NF-κB和谷胱甘肽相结合可增强其抗肿瘤效果。” [Eur. J. Pharm. Biopharm. 155 (2020) 162–176]

